Recurrent stroke secondary to late patent foramen ovale-closure device thrombus: a case report.
Case report
Myelofibrosis
PFO closure device
Patent foramen ovale
Stroke
Thrombus
Journal
European heart journal. Case reports
ISSN: 2514-2119
Titre abrégé: Eur Heart J Case Rep
Pays: England
ID NLM: 101730741
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
13
02
2021
revised:
29
03
2021
accepted:
22
07
2021
entrez:
23
8
2021
pubmed:
24
8
2021
medline:
24
8
2021
Statut:
epublish
Résumé
Percutaneous patent foramen ovale (PFO) closure has been well established in the secondary prevention of cryptogenic stroke with overall low rates of procedural complications. One such complication is PFO closure device thrombus formation which is now rarely reported with newer generation devices. We present the unusual case of a 59-year-old woman with myelofibrosis who developed late-onset recurrent embolic strokes related to Amplatzer PFO closure device thrombus whilst therapeutically anticoagulated on Warfarin. Surgical management was deemed too high risk and our patient was conservatively managed with enoxaparin. Serial transthoracic echocardiography demonstrated a reduction in thrombus size and the patient had no further neurological events. Overall, the risk of serious complications following percutaneous PFO closure, such as device-associated thrombus, remains low. The risk of thrombus formation in patients with hypercoagulable states is not well characterized. Despite good evidence for the efficacy in preventing recurrent cryptogenic stroke, the role of PFO closure in addition to anticoagulation is unclear. Given this uncertain benefit of PFO closure in anticoagulated patients and the unclear risk profile, patient selection, and thorough pre-procedural evaluation are vital when assessing the appropriateness of percutaneous PFO closure.
Sections du résumé
BACKGROUND
BACKGROUND
Percutaneous patent foramen ovale (PFO) closure has been well established in the secondary prevention of cryptogenic stroke with overall low rates of procedural complications. One such complication is PFO closure device thrombus formation which is now rarely reported with newer generation devices.
CASE SUMMARY
METHODS
We present the unusual case of a 59-year-old woman with myelofibrosis who developed late-onset recurrent embolic strokes related to Amplatzer PFO closure device thrombus whilst therapeutically anticoagulated on Warfarin. Surgical management was deemed too high risk and our patient was conservatively managed with enoxaparin. Serial transthoracic echocardiography demonstrated a reduction in thrombus size and the patient had no further neurological events.
DISCUSSION
CONCLUSIONS
Overall, the risk of serious complications following percutaneous PFO closure, such as device-associated thrombus, remains low. The risk of thrombus formation in patients with hypercoagulable states is not well characterized. Despite good evidence for the efficacy in preventing recurrent cryptogenic stroke, the role of PFO closure in addition to anticoagulation is unclear. Given this uncertain benefit of PFO closure in anticoagulated patients and the unclear risk profile, patient selection, and thorough pre-procedural evaluation are vital when assessing the appropriateness of percutaneous PFO closure.
Identifiants
pubmed: 34423249
doi: 10.1093/ehjcr/ytab313
pii: ytab313
pmc: PMC8377246
doi:
Types de publication
Case Reports
Langues
eng
Pagination
ytab313Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.
Références
Eur J Echocardiogr. 2007 Jan;8(1):53-6
pubmed: 16337834
J Stroke Cerebrovasc Dis. 2016 Sep;25(9):e161-2
pubmed: 27444520
N Engl J Med. 2017 Sep 14;377(11):1033-1042
pubmed: 28902580
J Am Coll Cardiol. 2018 May 22;71(20):2335-2342
pubmed: 29544871
Congenit Heart Dis. 2009 Jul-Aug;4(4):252-7
pubmed: 19664027
N Engl J Med. 2017 Sep 14;377(11):1011-1021
pubmed: 28902593
N Engl J Med. 2013 Mar 21;368(12):1092-100
pubmed: 23514286
J Am Coll Cardiol. 2004 Jan 21;43(2):302-9
pubmed: 14736453
Neurology. 2001 Oct 9;57(7):1330-2
pubmed: 11591862
Circulation. 2000 Feb 29;101(8):893-8
pubmed: 10694529
JACC Cardiovasc Interv. 2009 Feb;2(2):116-23
pubmed: 19463412
Am J Cardiol. 2008 May 1;101(9):1353-8
pubmed: 18435971
N Engl J Med. 2012 Mar 15;366(11):991-9
pubmed: 22417252
N Engl J Med. 2013 Mar 21;368(12):1083-91
pubmed: 23514285
Cathet Cardiovasc Diagn. 1998 Jan;43(1):81-3
pubmed: 9473199